127 related articles for article (PubMed ID: 21407161)
1. Expression of somatostatin receptor subtypes in primary and recurrent gonadotropinomas: are somatostatin receptors involved in pituitary adenoma recurrence?
Pisarek H; Kunert-Radek J; Radek M; Swietoslawski J; Winczyk K; Pawlikowski M
Neuro Endocrinol Lett; 2011; 32(1):96-101. PubMed ID: 21407161
[TBL] [Abstract][Full Text] [Related]
2. Expression of somatostatin receptor subtypes in human pituitary adenomas -- immunohistochemical studies.
Pisarek H; Pawlikowski M; Kunert-Radek J; Radek M
Endokrynol Pol; 2009; 60(4):240-51. PubMed ID: 19753537
[TBL] [Abstract][Full Text] [Related]
3. SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary.
Lee M; Lupp A; Mendoza N; Martin N; Beschorner R; Honegger J; Schlegel J; Shively T; Pulz E; Schulz S; Roncaroli F; Pellegata NS
Endocr Relat Cancer; 2015 Feb; 22(1):111-9. PubMed ID: 25515731
[TBL] [Abstract][Full Text] [Related]
4. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
[TBL] [Abstract][Full Text] [Related]
5. Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study.
Ramírez C; Cheng S; Vargas G; Asa SL; Ezzat S; González B; Cabrera L; Guinto G; Mercado M
J Clin Endocrinol Metab; 2012 May; 97(5):1745-51. PubMed ID: 22419713
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor subtype gene expression in pituitary adenomas.
Miller GM; Alexander JM; Bikkal HA; Katznelson L; Zervas NT; Klibanski A
J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
[TBL] [Abstract][Full Text] [Related]
7. Pituitary adenoma: a DNA flow cytometric study of 192 clinicopathologically characterized tumors.
Gaffey TA; Scheithauer BW; Leech RW; Blick K; Kovacs K; Horvath E; Weaver AL; Lloyd RV; Ebersold M; Laws ER; DeBault LE
Clin Neuropathol; 2005; 24(2):56-63. PubMed ID: 15803804
[TBL] [Abstract][Full Text] [Related]
8. Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo.
Nielsen S; Mellemkjaer S; Rasmussen LM; Ledet T; Olsen N; Bojsen-Møller M; Astrup J; Weeke J; Jørgensen JO
J Endocrinol Invest; 2001 Jun; 24(6):430-7. PubMed ID: 11434667
[TBL] [Abstract][Full Text] [Related]
9. Effects of somatostatin on vascular endothelial growth factor (VEGF) secretion from non-functioning pituitary tumoral cells incubated in vitro.
Ławnicka H; Pisarek H; Kunert-Radek J; Pawlikowski M
Neuro Endocrinol Lett; 2008 Feb; 29(1):113-6. PubMed ID: 18283262
[TBL] [Abstract][Full Text] [Related]
10. Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?
Rass L; Rahvar AH; Matschke J; Saeger W; Renné T; Aberle J; Flitsch J; Rotermund R
Hormones (Athens); 2022 Mar; 21(1):79-89. PubMed ID: 34674191
[TBL] [Abstract][Full Text] [Related]
11. Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.
Padova H; Rubinfeld H; Hadani M; Cohen ZR; Nass D; Taylor JE; Culler MD; Shimon I
Mol Cell Endocrinol; 2008 May; 286(1-2):214-8. PubMed ID: 18276067
[TBL] [Abstract][Full Text] [Related]
12. Estrogen Receptor α, a Sex-Dependent Predictor of Aggressiveness in Nonfunctioning Pituitary Adenomas: SSTR and Sex Hormone Receptor Distribution in NFPA.
Øystese KA; Casar-Borota O; Normann KR; Zucknick M; Berg JP; Bollerslev J
J Clin Endocrinol Metab; 2017 Sep; 102(9):3581-3590. PubMed ID: 28911153
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of somatostatin receptor subtype 5 (SSTR-5) in cushing adenoma.
Hassaneen W; Cahill DP; Fuller GN; Levine NB
J Neurooncol; 2010 May; 98(1):151-2. PubMed ID: 19894022
[No Abstract] [Full Text] [Related]
15. Expression of somatostatin receptors, angiogenesis and proliferation markers in pituitary adenomas: an immunohistochemical study with diagnostic and therapeutic implications.
Magagna-Poveda A; Leske H; Schmid C; Bernays R; Rushing EJ
Swiss Med Wkly; 2013; 143():w13895. PubMed ID: 24222652
[TBL] [Abstract][Full Text] [Related]
16. The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro.
Gruszka A; Kunert-Radek J; Radek A; Pisarek H; Taylor J; Dong JZ; Culler MD; Pawlikowski M
Life Sci; 2006 Jan; 78(7):689-93. PubMed ID: 16115652
[TBL] [Abstract][Full Text] [Related]
17. The identification of human pituitary adenoma-initiating cells.
Manoranjan B; Mahendram S; Almenawer SA; Venugopal C; McFarlane N; Hallett R; Vijayakumar T; Algird A; Murty NK; Sommer DD; Provias JP; Reddy K; Singh SK
Acta Neuropathol Commun; 2016 Nov; 4(1):125. PubMed ID: 27894339
[TBL] [Abstract][Full Text] [Related]
18. Gene transcription of receptors for growth hormone-releasing peptide and somatostatin in human pituitary adenomas.
Nielsen S; Mellemkjaer S; Rasmussen LM; Ledet T; Astrup J; Weeke J; Jørgensen JO
J Clin Endocrinol Metab; 1998 Aug; 83(8):2997-3000. PubMed ID: 9709982
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
Danila DC; Haidar JN; Zhang X; Katznelson L; Culler MD; Klibanski A
J Clin Endocrinol Metab; 2001 Jul; 86(7):2976-81. PubMed ID: 11443154
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor profile in pituitary thyrotroph adenomas.
Thodou E; Kontogeorgos G
Clin Neurol Neurosurg; 2020 Aug; 195():105865. PubMed ID: 32416325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
